| Literature DB >> 22954136 |
Katherine S Ong1, Rob Carter, Margaret Kelaher, Ian Anderson.
Abstract
BACKGROUND: Health economics is increasingly used to inform resource allocation decision-making, however, there is comparatively little evidence relevant to minority groups. In part, this is due to lack of cost and effectiveness data specific to these groups upon which economic evaluations can be based. Consequently, resource allocation decisions often rely on mainstream evidence which may not be representative, resulting in inequitable funding decisions. This paper describes a method to overcome this deficiency for Australia's Indigenous population. A template has been developed which can adapt mainstream health intervention data to the Indigenous setting.Entities:
Mesh:
Year: 2012 PMID: 22954136 PMCID: PMC3468365 DOI: 10.1186/1472-6963-12-307
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Summary of key informant characteristics
| Urban – Melbourne | 3 | 2 | | 2 | | |
| Rural - Victoria | | 1 | | | | |
| Remote – Central Australia and Northern Territory | 1 | 4 | 2 | | 1 | |
AHW = Aboriginal Health Worker.
The additional cost of IHSD Template components (averaged across total Indigenous population) (Reproduced from Ong [17])
| Basic health intervention delivery characteristics | $16.67-$31.57 (depending on consultation length) |
| Population health, social and community activities | $9.28 |
| Management and governance | $3.87 |
| Patient transport services | $47.01 |
| Services to remote regions | $5.50 |
IHSD Template values for total Indigenous population (including 95% uncertainty ranges)
| $ 30.85 | $ 113.18 ($78.74–$149.43) | $ 91.21 ($59.93–$127.80) | $ 168.36 ($104.00–$235.42) | |
| $ 58.55 | $ 155.78 ($101.76–$220.13) | $ 129.34 ($76.99–$187.94) | $ 223.42 ($134.49–$319.30) | |
| 1 | 1.16 (1.13–1.18) | 1 | 1.60 (1.51–1.69) | |
| 60.0% (50.8%–69.6%) | 73.2% (63.0%–82.6%) | As for total Indigenous pop* | As for total Indigenous pop* | |
| 77.8% (65.7%–89.7%) | 95.7% (83.5%–108.3%) | As for total Indigenous pop* | As for total Indigenous pop* | |
| 1.19 (0.96–1.49) | 1.19 (0.96–1.49) | As for total Indigenous pop* | As for total Indigenous pop* | |
* Indigenous utilization and adherence rates and cost-offsets were not assessed separately for the non-remote and remote populations, so values calculated are those for the total Indigenous population.
Intervention parameters for the polypill intervention (Year 1 shown only)
| ·RR Acute coronary syndrome | 0.45 | 0.45 | 0.45 |
| ·RR stroke | 0.31 | 0.31 | 0.31 |
| ·1 Long consultation | $58.55 | $58.55 | $155.78* |
| ·2 Short consultations | $61.70 | $61.70 | $226.36* |
| ·Medication | $500.00 | $500.00 | $500.00 |
| ·Pathology tests | $43.62 | $43.62 | $50.60* ($43.62 x 1.16) |
| 82% | 49.2%* (82% x 60%) | 60%* (82% x 73.2%) | |
| 60% | 46.7%* (60% x 77.8%) | 57.4%* (60% x 95.7%) | |
| $11,078 | $13,183* ($11,078 x 1.19) | $13,183* ($11,078 x 1.19) | |
* Indicates values for which the IHSD Template (from Table 3) has been applied (calculations in parentheses).
Cost-effectiveness of the polypill priced at $500 in preventing CVD
| Total Australian aged 55+ | Mainstream GP practice | 1000000 | 12000 | 11000 |
| Total Indigenous aged 55+ | Mainstream GP practice | 550 | 7.2 | 13000 |
| Total Indigenous aged 55+ | ACCHS | 830 | 17 | 21000 |